EGFR Mutation Impact on Definitive Concurrent Chemoradiation Therapy for Inoperable Stage III Adenocarcinoma-Reference-Cited by-同舟云学术

EGFR Mutation Impact on Definitive Concurrent Chemoradiation Therapy for Inoperable Stage III Adenocarcinoma

Published:2015-12 Issue:12 Volume:10 Page:1720-1725
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Tanaka Kosuke,Hida Toyoaki,Oya Yuko,Oguri Tomoyo,Yoshida Tatsuya,Shimizu Junichi,Horio Yoshitsugu,Hata Akito,Kaji Reiko,Fujita Shiro,Sekido Yoshitaka,Kodaira Takeshi,Kokubo Masaki,Katakami Nobuyuki,Yatabe Yasushi

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference24 articles.

1. Cancer burden in the year 2000: the global picture;Parkin;Eur J Cancer,2001

2. Definitive chemoradiation for the treatment of locally advanced non small-cell lung cancer;Blackstock;J Clin Oncol,2007

3. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer;Furuse;J Clin Oncol,1999

4. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003;Pfister;J Clin Oncol,2004

5. Overview of chemoradiation clinical trials for locally advanced non-small cell lung cancer in Japan;Okamoto;Int J Clin Oncol,2008

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study;Journal of Thoracic Oncology;2024-06

2. Clinical features and outcomes of unresectable locally advanced non-small cell lung cancer with uncommon EGFR Mutations: A retrospective multi-center Chinese study;2024-03-25

3. Durvalumab after chemoradiotherapy in non‐small cell lung cancer with EGFR mutation: A real‐world study (HOT2101);Cancer Science;2024-01-29

4. Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives;Lung Cancer;2024-01

5. Traitement standard des stades III non résécables;Revue des Maladies Respiratoires Actualités;2023-10